Atea Pharmaceuticals (AVIR) Share-based Compensation (2019 - 2026)

Atea Pharmaceuticals' Share-based Compensation history runs 8 years deep, the most recent figure standing at $16.3 million for Q1 2026.

• In Q1 2026, Share-based Compensation rose 134.9% year-over-year to $16.3 million; the TTM figure through Mar 2026 stood at $16.3 million (down 64.93% YoY), while the FY2025 annual figure was $13.2 million, down 74.43% from the prior year.
• Share-based Compensation for Q1 2026 stood at $16.3 million, up from -$15.6 million in the prior quarter.
• The five-year high for Share-based Compensation was $43.8 million in Q4 2022, with the low at -$15.6 million in Q4 2025.
• The 5-year median for Share-based Compensation is $12.5 million (2023), against an average of $13.7 million.
• The sharpest annual moves came in 2023 and 2025: Share-based Compensation surged 326.65% in 2023, then sank 209.46% in 2025.
• Atea Pharmaceuticals' Share-based Compensation stood at $43.8 million in 2022, then tumbled by 72.23% to $12.2 million in 2023, then rose by 17.6% to $14.3 million in 2024, then tumbled by 209.46% to -$15.6 million in 2025, then jumped by 204.33% to $16.3 million in 2026.
• Business Quant data shows AVIR's Share-based Compensation at $16.3 million in Q1 2026, -$15.6 million in Q4 2025, and $15.9 million in Q3 2025.